胃癌分子靶向治疗的现状与进展

胃癌是对人类健康危害极大的常见恶性肿瘤,大部分患者就诊时已进入进展期.我国胃癌的年死亡率在各种恶性肿瘤中占首位.随着外科手术技术的提高、传统放化疗技术的进步以及新辅助疗法的实施,早期胃癌术后5a生存率可达95%以上;而进展期胃癌疗效仍不理想,术后5a生存率仅有30%-40%.随着胃癌分子生物学研究的不断深入,针对肿瘤细胞生长、凋亡、细胞周期、侵袭浸润以及血管生成等分子生物靶点提出的分子靶向治疗成为胃癌综合治疗的重点和热点.这些策略主要包括:表皮生长因子受体靶向治疗,细胞周期抑制剂,细胞凋亡促进剂,血管生成抑制剂,基质金属蛋白酶抑制剂等.本文收集国内外近期文献就胃癌分子靶向治疗的现状与进展进行综述.

Current status and recent developments in molecular targeted therapy against gastric cancer

Gastric cancer (GC) is one of the most common malignancies of the digestive system and is a major cause of cancer death in China.Recent improvements in both surgical techniques and adjuvant/neoadjuvant chemotherapy, radiotherapy or both have increased the survival rate of patients with early-stage disease.However,most patients with GC have advanced disease at diagnosis.Thus,despite recent advances,these patients still do poorly. Understanding the molecular pathways that characterize cell growth,cell cycle,apoptosis, angiogenesis and invasion has enabled us to use new approaches to treat this disease in clinical situations.These therapeutic strategies include epidermal growth factor receptor inhibitors,angiogenesis inhibitors,cell cycle inhibitors,apoptosis promoters and matrix metalloproteinase inhibitors.This review presents a brief introduction to the current status and advancement of molecular targeted therapies in the treatment of GC.